Frost & Sullivan Publishes Q3-2018 Update On Cellect Biotechnology Ltd.
TEL AVIV, Israel, Dec. 13, 2018 /PRNewswire/ -- Cellect Biotechnology Ltd. is developing a technological platform, the "ApoGraft", which functionally selects stem cells from a mixed population of cells based on their sensitivity to apoptosis. The first product under development is the ApoTainertm selection kit. The company is currently conducting a proof-of-concept phase I/II trial with blood cancer patients in Israel, which is expected to be completed by the end of Q3-2018. Based on trial results and safety issues, the company plans to integrate its technology into a range of procedures that utilize stem cells, as well as into the manufacturing process of adult stem cell based products.
Summary of Highlights
Below are the highlights of Cellect's Q3 report released on Nov.13, 2018:
ApoGraft POC final results by mid-2019; Cellect continues to strengthen its IP portfolio for stem cell therapy related technologies and build a line of partnerships. The company announced the following:
Opened a second site for the company's ongoing clinical trial which allowed it to expedite the recruitment of additional patients and as a result, half of the patients planned for the study have finished first month follow up and all patients have shown 100% engraftment with no procedure related adverse events. The first three patients of the trial (cohort I) have completed the study period (180 days) with full safety and tolerability.
Achieved positive results on the use of fat derived cells treated with the ApoGrafttm process in orthopedic treatments in an animal model and announced that it has successfully developed its new first in kind technology as an integral part of Cellect's ApoTainertm for industrialization. The new technology utilizes FasL-coated magnetic beads for maximizing efficacy and scalability of stem cell-based product manufacturing. The ApoTainertm improves the uniformity and hence quality of the outcome thereby supporting the safety and efficacy of raw material (stem cells) for all cell therapies.
Received a formal Notice of Allowance from the Japanese and Australian Patent Offices for patents & trademarks.
Sufficient cash to support current early phase and pre-clinical pipeline developments until Q2-2019.
Cash and cash equivalents and marketable securities totaled $6.45 million as of September 30, 2018, compared to $8.26 million on June 30, 2018. The change is primarily due to net proceeds of $3.5 million from a registered direct offering completed in January 2018 being offset by cash used in operations during the period.
We maintain our estimation of the company's equity value at $101.4M; corresponding to a target price ranging between $15.40 and $18.70; a mean of $16.90.
The company is on track to meet its strategic goals. Should the company see positive results in its ongoing trial (ApoGraft POC final results estimated for early 2019) the target price of their stock is projected to increase accordingly.
Frost & Sullivan, the Growth Partnership Company, works in collaboration with clients to leverage visionary innovation that addresses the global challenges and related growth opportunities that will make or break today's market participants. For more than 50 years, we have been developing growth strategies for the global 1000, emerging businesses, the public sector and the investment community. Contact us: Start the discussion
Onto Innovation Inc. today announced the release of a new sub-surface inspection capability for the Dragonfly® G3 sub-micron 2D/3D inspection and metrology platform. The new capability enables whole wafer inspection for critical yield impacting...
Agenus Inc. ("Agenus") , a leader in developing novel immunological agents to treat various cancers, today announced the Company will release its first quarter 2024 financial results before the market opens on Tuesday, May 7, 2024. Agenus executives...
Tharimmune, Inc. ("Tharimmune" or the "Company"), a clinical-stage biotechnology company developing a portfolio of therapeutic candidates in inflammation & immunology, announced today an option agreement for an...
Causal IQ is proud to announce that it has been awarded three coveted Pollie Awards from the American Association of Political Consultants (AAPC), the industry's highest honor bestowed upon political consultants at the national and international...
Venuetize, Everi Holdings Inc.'s ("Everi" or "the Company") leading mobile technology and advanced e-commerce platform for the sports, hospitality, and entertainment industries, today announced it has been selected by Oak View Group ("OVG") as the...
goeasy Ltd. , ("goeasy" or the "Company"), one of Canada's leading consumer lenders focused on delivering a full suite of financial services to non-prime Canadians, is pleased to release its first quarter 2024 results after the market closes on...